Aprogen Turns To IPO To Support Biosimilar Pipeline Expansion
This article was originally published in PharmAsia News
Executive Summary
South Korea's Aprogen, which has reached global partnership with Japan's Nichi-Iko for development of its biosimilar versions of Remicade, Herceptin and Rituxan/Mab Thera, is seeking to independently conduct clinical development of other biosimilar products by using the proceeds from its domestic initial public offering.
You may also be interested in...
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.